Bixia Tang

ORCID

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 11

Top Venues

Journal for immunotherapy of cancer

The oncologist

This page only lists publications with an associated author ORCID identifier.

Publications

Bixia Tang, Rong Duan, Xiaoshi Zhang, Shuikui Qin, Di Wu, Jing Chen, Hong Yao, Zhihong Chi, Jun Guo, Xieqiao Yan
Five-Year Follow-Up of POLARIS-01 Phase II Trial: Toripalimab as Salvage Monotherapy in Chinese Patients With Advanced Melanoma. The oncologist 29 (6) (2024)
Bixia Tang, Rong Duan, Xiaoshi Zhang, Shuikui Qin, Di Wu, Jing Chen, Hong Yao, Zhihong Chi, Jun Guo, Xieqiao Yan
Five-Year Follow-Up of POLARIS-01 Phase II Trial: Toripalimab as Salvage Monotherapy in Chinese Patients With Advanced Melanoma. The oncologist 29 (6) (2024)
Bixia Tang, Rong Duan, Xiaoshi Zhang, Shuikui Qin, Di Wu, Jing Chen, Hong Yao, Zhihong Chi, Jun Guo, Xieqiao Yan
Five-Year Follow-Up of POLARIS-01 Phase II Trial: Toripalimab as Salvage Monotherapy in Chinese Patients With Advanced Melanoma. The oncologist (2024)
Bixia Tang, Rong Duan, Xiaoshi Zhang, Shuikui Qin, Di Wu, Jing Chen, Hong Yao, Zhihong Chi, Jun Guo, Xieqiao Yan
Five-Year Follow-Up of POLARIS-01 Phase II Trial: Toripalimab as Salvage Monotherapy in Chinese Patients With Advanced Melanoma. The oncologist 29 (6) (2024)
Li Zhou, Min Cao, Haibin Zhu, Zhihong Chi, Chuanliang Cui, Xinan Sheng, Lili Mao, Bin Lian, Bixia Tang, Xieqiao Yan, Xue Bai, Xuan Wang, Siming Li, Jun Guo, Ying-Shi Sun, Lu Si
Predominance of hyperprogression in mucosal melanoma during anti-PD-1 monotherapy treatment. The oncologist (2024)
Jie Dai, Xue Bai, Xuan Gao, Lirui Tang, Yu Chen, Linzi Sun, Xiaoting Wei, Caili Li, Zhonghui Qi, Yan Kong, Chuanliang Cui, Zhihong Chi, Xinan Sheng, Zelong Xu, Bin Lian, Siming Li, Xieqiao Yan, Bixia Tang, Li Zhou, Xuan Wang, Xuefeng Xia, Jun Guo, Lili Mao, Lu Si
Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy. Journal for immunotherapy of cancer 11 (1) (2023)
Jie Dai, Xue Bai, Xuan Gao, Lirui Tang, Yu Chen, Linzi Sun, Xiaoting Wei, Caili Li, Zhonghui Qi, Yan Kong, Chuanliang Cui, Zhihong Chi, Xinan Sheng, Zelong Xu, Bin Lian, Siming Li, Xieqiao Yan, Bixia Tang, Li Zhou, Xuan Wang, Xuefeng Xia, Jun Guo, Lili Mao, Lu Si
Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy. Journal for immunotherapy of cancer 11 (1) (2023)
Jie Dai, Xue Bai, Xuan Gao, Lirui Tang, Yu Chen, Linzi Sun, Xiaoting Wei, Caili Li, Zhonghui Qi, Yan Kong, Chuanliang Cui, Zhihong Chi, Xinan Sheng, Zelong Xu, Bin Lian, Siming Li, Xieqiao Yan, Bixia Tang, Li Zhou, Xuan Wang, Xuefeng Xia, Jun Guo, Lili Mao, Lu Si
Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy. Journal for immunotherapy of cancer 11 (1) (2023)
Xue Bai, Michelle Kim, Gyulnara Kasumova, Lu Si, Bixia Tang, Chuanliang Cui, Xiaoling Yang, Xiaoting Wei, Justine Cohen, Donald Lawrence, Christine Freedman, Riley Fadden, Krista Rubin, Tatyana Sharova, Dennie Frederick, Keith Flaherty, Ryan Sullivan, Jun Guo, Genevieve Marie Boland
Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort. Journal for immunotherapy of cancer 9 (2) (2022)
Siming Li, Xiaowen Wu, Xieqiao Yan, Li Zhou, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Lili Mao, Bin Lian, Xuan Wang, Xue Bai, Jie Dai, Yan Kong, Xiongwen Tang, Hui Feng, Sheng Yao, Keith T Flaherty, Jun Guo, Xinan Sheng
Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis. Journal for immunotherapy of cancer 10 (2) (2022)
ChuanLiang Cui, Xuan Wang, Bin Lian, Qing Ji, Li Zhou, Zhihong Chi, Lu Si, Xinan Sheng, Yan Kong, Jiayi Yu, Siming Li, Lili Mao, Bixia Tang, Jie Dai, Xieqiao Yan, Xue Bai, Robert H I Andtbacka, Jun Guo
OrienX010, an oncolytic virus, in patients with unresectable stage IIIC-IV melanoma: a phase Ib study. Journal for immunotherapy of cancer 10 (4) (2022)

Bixia Tang.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Bixia Tang